Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma (Q39040044)

From Wikidata

Jump to navigation Jump to search

scientific article published on 4 January 2017

Language	Label	Description	Also known as
English	Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma	scientific article published on 4 January 2017

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

10 January 2018

http://europepmc.org/abstract/PMC/5496796

Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma (English)

1 reference

Europe PubMed Central

PMC publication ID

10 January 2018

http://europepmc.org/abstract/PMC/5496796

1 reference

based on heuristic

inferred from title

13

object named as

Sagar Lonial

1 reference

Europe PubMed Central

10 January 2018

PMC publication ID

Paul G. Richardson

4

object named as

Paul Richardson

1 reference

Europe PubMed Central

PMC publication ID

10 January 2018

http://europepmc.org/abstract/PMC/5496796

Robert Z Orlowski

6

object named as

Robert Orlowski

1 reference

Europe PubMed Central

PMC publication ID

10 January 2018

http://europepmc.org/abstract/PMC/5496796

author name string

Dan T Vogl

1

1 reference

Europe PubMed Central

PMC publication ID

10 January 2018

http://europepmc.org/abstract/PMC/5496796

Noopur Raje

2

1 reference

Europe PubMed Central

PMC publication ID

10 January 2018

http://europepmc.org/abstract/PMC/5496796

Sundar Jagannath

3

1 reference

Europe PubMed Central

PMC publication ID

10 January 2018

http://europepmc.org/abstract/PMC/5496796

Parameswaran Hari

5

1 reference

Europe PubMed Central

PMC publication ID

10 January 2018

http://europepmc.org/abstract/PMC/5496796

Jeffrey G Supko

7

1 reference

Europe PubMed Central

PMC publication ID

10 January 2018

http://europepmc.org/abstract/PMC/5496796

David Tamang

8

1 reference

Europe PubMed Central

PMC publication ID

10 January 2018

http://europepmc.org/abstract/PMC/5496796

Min Yang

9

1 reference

Europe PubMed Central

PMC publication ID

10 January 2018

http://europepmc.org/abstract/PMC/5496796

Simon S Jones

10

1 reference

Europe PubMed Central

PMC publication ID

10 January 2018

http://europepmc.org/abstract/PMC/5496796

Catherine Wheeler

11

1 reference

Europe PubMed Central

PMC publication ID

10 January 2018

http://europepmc.org/abstract/PMC/5496796

Robert J Markelewicz

12

1 reference

Europe PubMed Central

PMC publication ID

10 January 2018

http://europepmc.org/abstract/PMC/5496796

language of work or name

0 references

publication date

4 January 2017

1 reference

Europe PubMed Central

PMC publication ID

10 January 2018

http://europepmc.org/abstract/PMC/5496796

Clinical Cancer Research

1 reference

Europe PubMed Central

PMC publication ID

10 January 2018

http://europepmc.org/abstract/PMC/5496796

23

1 reference

Europe PubMed Central

PMC publication ID

10 January 2018

http://europepmc.org/abstract/PMC/5496796

13

1 reference

Europe PubMed Central

PMC publication ID

10 January 2018

http://europepmc.org/abstract/PMC/5496796

3307-3315

1 reference

Europe PubMed Central

PMC publication ID

10 January 2018

http://europepmc.org/abstract/PMC/5496796

Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5496796

17 June 2018

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5496796

17 June 2018

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5496796

17 June 2018

Rational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5496796

17 June 2018

Ricolinostat (ACY-1215) induced inhibition of aggresome formation accelerates carfilzomib-induced multiple myeloma cell death

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5496796

17 June 2018

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5496796

17 June 2018

International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5496796

17 June 2018

Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5496796

17 June 2018

Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5496796

17 June 2018

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5496796

17 June 2018

Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5496796

17 June 2018

Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5496796

17 June 2018

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5496796

17 June 2018

Autophagy fights disease through cellular self-digestion

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5496796

17 June 2018

Linking of autophagy to ubiquitin-proteasome system is important for the regulation of endoplasmic reticulum stress and cell viability

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5496796

17 June 2018

Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5496796

17 June 2018

The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5496796

17 June 2018

The Functional Assessment of Cancer Therapy scale: development and validation of the general measure

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5496796

17 June 2018

Histone deacetylase (HDAC) inhibitors as single agents induce multiple myeloma cell death principally through the inhibition of class I HDAC.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5496796

21 August 2018

Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5496796

21 August 2018

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5496796

21 August 2018

Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5496796

2 December 2018

Identifiers

10.1158/1078-0432.CCR-16-2526

1 reference

Europe PubMed Central

PMC publication ID

10 January 2018

http://europepmc.org/abstract/PMC/5496796

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

10 January 2018

http://europepmc.org/abstract/PMC/5496796

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

10 January 2018

http://europepmc.org/abstract/PMC/5496796

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39040044&oldid=1804991031"